INSMED Inc
For the period ended Sep 30, 2025. Filed Oct 30, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 30, 2025
INSM$119.49+2.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows (unaudited) for the and
Consolidated Statements of Cash Flows (unaudited)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities | ||
| Net loss | $(948,290) | $(678,224) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 6,825 | 4,483 |
| Amortization of intangible assets | 4,064 | 3,789 |
| Stock-based compensation expense | 113,671 | 70,281 |
| Amortization of debt issuance costs | 4,840 | 5,136 |
| Paid-in-kind interest capitalized | — | 19,233 |
| Royalty financing non-cash interest expense | 15,344 | 14,979 |
| Accretion of discount on marketable securities, net | (27,951) | (8,133) |
| Finance lease amortization expense | 2,034 | 2,034 |
| Non-cash operating lease expense | 2,748 | 2,230 |
| Change in fair value of deferred and contingent consideration liabilities | 181,953 | 106,482 |
| Change in fair value of interest rate swap | — | 1,106 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (11,007) | (1,115) |
| Inventory | (19,755) | (14,922) |
| Prepaid expenses and other current assets | (27,207) | (16,981) |
| Other assets | 9,664 | 5,625 |
| Accounts payable and accrued liabilities | 9,727 | 3,462 |
| Other liabilities | (4,078) | (7,368) |
| Net cash used in operating activities | (687,418) | (487,903) |
| Investing activities | ||
| Purchase of fixed assets | (15,972) | (15,151) |
| Purchase of marketable securities | (2,092,014) | (999,782) |
| Maturities of marketable securities | 1,654,000 | 300,000 |
| Net cash used in investing activities | (453,986) | (714,933) |
| Financing activities | ||
| Proceeds from exercise of stock options and ESPP | 101,082 | 99,503 |
| Proceeds from issuance of common stock, net | 823,282 | 1,084,136 |
| Payments of principal of 0.75% convertible senior notes due 2028 | (1,965) | — |
| Payments of finance lease principal | (2,185) | (1,924) |
| Net cash provided by financing activities | 920,214 | 1,181,715 |
| Effect of exchange rates on cash and cash equivalents | 924 | 198 |
| Net decrease in cash and cash equivalents | (220,266) | (20,923) |
| Cash and cash equivalents at beginning of period | 555,030 | 482,374 |
| Cash and cash equivalents at end of period | $334,764 | $461,451 |
| Supplemental disclosures of cash flow information: | ||
| Cash paid for interest | $41,843 | $25,327 |
| Cash paid for income taxes | $4,030 | $2,251 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.